– USA, CA –  Cardiva Medical, Inc., an innovator in the field of vascular closure, today announced the appointment of medical device expert Jeryl Hilleman to the company’s Board of Directors.

“We are thrilled to welcome Jeri to our team and look forward to leveraging her deep expertise with high-growth medical device companies and in building global markets for innovative technologies,” said John Russell, president and CEO of Cardiva Medical, Inc. “We believe that Jeri’s dynamic experience will help strengthen our position as a leader in vessel closure for coronary, peripheral and electrophysiology procedures as we continue to accelerate Cardiva’s exciting growth.”

Ms. Hilleman currently serves on the board of directors and as the audit committee chair of Novocure (Nasdaq: NVCR), Minerva (Nasdaq: NERV) and SI-Bone (Nasdaq: SIBN). She most recently served as CFO of Intersect ENT (Nasdaq: XENT).

“Cardiva Medical has emerged as a leader in vascular closure,” said Hilleman. “I look forward to working with the Cardiva Board and leadership team to expand the reach of Cardiva’s portfolio of vascular closure devices to even more patients, physicians and health systems.”

About Cardiva Medical, Inc.

Cardiva Medical, Inc. is a privately held medical device company focused on transforming vascular closure for the benefit of patients, hospitals and physicians in the over 5.5 million catheter-based coronary, peripheral and electrophysiology procedures in the United States that require access site closure each year.

The Company’s VASCADE vascular closure system has been PMA-approved by the FDA since 2013 and is indicated for vessel closure following 5-7F arterial and venous procedures. VASCADE is the only marketed closure system to demonstrate a statistically significant reduction in access site complications compared to the existing standard of care in a prospective, randomized, controlled clinical trial called RESPECT. The latest product in the Company’s portfolio is VASCADE MVP Venous Vascular Closure System, the only marketed vessel closure technology designed specifically for Electrophysiology procedures – and clinically proven by Electrophysiology physicians in a multi-center, randomized, controlled clinical trial called AMBULATE. VASCADE MVP received PMA approval in late 2018.

Cardiva has won numerous recent awards for clinical, commercial and operational excellence – including the Shingo Bronze Medallion. The Company is headquartered in Santa Clara, California.

For more information: https://www.cardivamedical.com

- DisclaimerNews, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.

Comments are closed.